section name header

Pronunciation

PAK-li-tax-el

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: taxoids

Indications

High Alert

Paclitaxel:

Paclitaxel (albumin-bound):

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Cross the placenta.

Protein Binding: 89–98%.

Metabolism/Excretion: Highly metabolized by the liver primarily by the CYP2C8 and CYP3A4 isoenzymes; <10% excreted unchanged in urine.

Half-life: Paclitaxel: 13–52 hr; Paclitaxel protein-bound particles (albumin-bound): 27 hr.

Time/Action Profile

(effect on WBCs)

ROUTEONSETPEAKDURATION
IVunknown11 days3 wk

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ECG changes, edema, hypotension, bradycardia.

Derm: alopecia, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

GI: liver enzymes, diarrhea, mucositis, nausea, vomiting, pancreatitis.

GU: renal failure.

Hemat: anemia, neutropenia, thrombocytopenia.

Local: injection site reactions.

MS: arthralgia, myalgia.

Neuro: peripheral neuropathy, dizziness, headache, seizures.

Resp: cough, dyspnea, interstitial pneumonia, PULMONARY EMBOLISM, PULMONARY FIBROSIS.
Misc: (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS , SEPSIS.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Paclitaxel

Ovarian Cancer

Paclitaxel Protein-Bound Particles (albumin-bound)

Breast Cancer

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Availability

Paclitaxel

(Generic available)

Paclitaxel Protein-Bound Particles (albumin-bound)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Taxol

paclitaxel protein-bound particles (Albumin-Bound): Abraxane